159 related articles for article (PubMed ID: 36206093)
1. Recent Apolipoprotein CIII trials.
Tramontano D; Bini S; D'Erasmo L; Arca M
Curr Opin Lipidol; 2022 Dec; 33(6):309-318. PubMed ID: 36206093
[TBL] [Abstract][Full Text] [Related]
2. ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen.
Rocha NA; East C; Zhang J; McCullough PA
Curr Atheroscler Rep; 2017 Nov; 19(12):62. PubMed ID: 29124482
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein CIII and diabetes. Is there a link?
Christopoulou E; Tsimihodimos V; Filippatos T; Elisaf M
Diabetes Metab Res Rev; 2019 Mar; 35(3):e3118. PubMed ID: 30557902
[TBL] [Abstract][Full Text] [Related]
4. Increased inflammation, endoplasmic reticulum stress and oxidative stress in endothelial and macrophage cells exacerbate atherosclerosis in ApoCIII transgenic mice.
Yingchun H; Yahong M; Jiangping W; Xiaokui H; Xiaohong Z
Lipids Health Dis; 2018 Sep; 17(1):220. PubMed ID: 30223835
[TBL] [Abstract][Full Text] [Related]
5. Updates on apolipoprotein CIII: fulfilling promise as a therapeutic target for hypertriglyceridemia and cardiovascular disease.
Zheng C
Curr Opin Lipidol; 2014 Feb; 25(1):35-9. PubMed ID: 24345989
[TBL] [Abstract][Full Text] [Related]
6. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E.
Ebara T; Ramakrishnan R; Steiner G; Shachter NS
J Clin Invest; 1997 Jun; 99(11):2672-81. PubMed ID: 9169497
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of ApoCIII: the next PCSK9?
Bernelot Moens SJ; van Capelleveen JC; Stroes ES
Curr Opin Lipidol; 2014 Dec; 25(6):418-22. PubMed ID: 25255477
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein CIII Deficiency Protects Against Atherosclerosis in Knockout Rabbits.
Yan H; Niimi M; Matsuhisa F; Zhou H; Kitajima S; Chen Y; Wang C; Yang X; Yao J; Yang D; Zhang J; Murakami M; Nakajima K; Wang Y; Liu E; Liang J; Chen YE; Fan J
Arterioscler Thromb Vasc Biol; 2020 Sep; 40(9):2095-2107. PubMed ID: 32757647
[TBL] [Abstract][Full Text] [Related]
9. The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia.
Morton AM; Furtado JD; Lee J; Amerine W; Davidson MH; Sacks FM
J Clin Lipidol; 2016; 10(6):1442-1451.e4. PubMed ID: 27919362
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteins.
Mendivil CO; Zheng C; Furtado J; Lel J; Sacks FM
Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):239-45. PubMed ID: 19910636
[TBL] [Abstract][Full Text] [Related]
11. APOC-III Antisense Oligonucleotides: A New Option for the Treatment of Hypertriglyceridemia.
Schmitz J; Gouni-Berthold I
Curr Med Chem; 2018; 25(13):1567-1576. PubMed ID: 28595549
[TBL] [Abstract][Full Text] [Related]
12. The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia.
Gouni-Berthold I
Atheroscler Suppl; 2017 Nov; 30():19-27. PubMed ID: 29096837
[TBL] [Abstract][Full Text] [Related]
13. ABCA1 promotes the de novo biogenesis of apolipoprotein CIII-containing HDL particles in vivo and modulates the severity of apolipoprotein CIII-induced hypertriglyceridemia.
Kypreos KE
Biochemistry; 2008 Sep; 47(39):10491-502. PubMed ID: 18767813
[TBL] [Abstract][Full Text] [Related]
14. Aggravated restenosis and atherogenesis in ApoCIII transgenic mice but lack of protection in ApoCIII knockouts: the effect of authentic triglyceride-rich lipoproteins with and without ApoCIII.
Li H; Han Y; Qi R; Wang Y; Zhang X; Yu M; Tang Y; Wang M; Shu YN; Huang W; Liu X; Rodrigues B; Han M; Liu G
Cardiovasc Res; 2015 Sep; 107(4):579-89. PubMed ID: 26160324
[TBL] [Abstract][Full Text] [Related]
15. ApoCIII: A multifaceted protein in cardiometabolic disease.
D'Erasmo L; Di Costanzo A; Gallo A; Bruckert E; Arca M
Metabolism; 2020 Dec; 113():154395. PubMed ID: 33058850
[TBL] [Abstract][Full Text] [Related]
16. Elevated Levels of Apolipoprotein CIII Increase the Risk of Postprandial Hypertriglyceridemia.
Guan Y; Hou X; Tian P; Ren L; Tang Y; Song A; Zhao J; Gao L; Song G
Front Endocrinol (Lausanne); 2021; 12():646185. PubMed ID: 33967959
[TBL] [Abstract][Full Text] [Related]
17. Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results.
Yang X; Lee SR; Choi YS; Alexander VJ; Digenio A; Yang Q; Miller YI; Witztum JL; Tsimikas S
J Lipid Res; 2016 Apr; 57(4):706-13. PubMed ID: 26848137
[TBL] [Abstract][Full Text] [Related]
18. Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells.
Kawakami A; Aikawa M; Libby P; Alcaide P; Luscinskas FW; Sacks FM
Circulation; 2006 Feb; 113(5):691-700. PubMed ID: 16461842
[TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein CIII may mediate the impacts of angiopoietin-like protein 8 on triglyceride metabolism.
Luo M; Su X; Yi Y; Yang Y; Peng D
Lipids Health Dis; 2018 Jul; 17(1):160. PubMed ID: 30021607
[TBL] [Abstract][Full Text] [Related]
20. Effect of the combination of methyltestosterone and esterified estrogens compared with esterified estrogens alone on apolipoprotein CIII and other apolipoproteins in very low density, low density, and high density lipoproteins in surgically postmenopausal women.
Chiuve SE; Martin LA; Campos H; Sacks FM
J Clin Endocrinol Metab; 2004 May; 89(5):2207-13. PubMed ID: 15126543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
